Valiant Laboratories Limited IPO Company Details:
Valiant Laboratories Limited is a manufacturer of Bulk Drugs and Active Pharmaceutical Ingredients (“API”) that specialises in Paracetamol production. Bulk drugs/Active Pharmaceutical Ingredients (API) serve as raw materials for manufacturing finished dosage forms or formulations. The company was originally formed in year 1980 as a partnership firm under the Indian Partnership Act, 1932 under the name and style of “M/s. Bharat Chemicals” and gradually, commenced manufacturing of Paracetamol by late 1982. In August 2021, this partnership firm was converted into a public limited company registered under the Companies Act.
Valiant Laboratories Limited IPO Business Offerings:
-
The company produces paracetamol in a variety of grades, including IP, BP, EP, and USP, in accordance with the pharmacopoeia needs of its clients.
Valiant Laboratories Limited’s manufacturing facility is located at Tarapur Industrial Area, Boisar, Palghar, in the state of Maharashtra, India which is spread over an aggregate parcel of land admeasuring about 2,000 square metres with an aggregate annual total installed capacity of 9,000 MT per annum. Within its Manufacturing Facility located at Tarapur Industrial Area, Palghar, Maharashtra it also have an in-house R&D infrastructure. The company plans to establish a greenfield project at Saykha Industrial Area, Bharuch, Gujarat, through its wholly owned subsidiary, Valiant Advanced Sciences Private Limited. The project will be spread out over an overall parcel of land with a total area of about 57,766 square metres and will focus on the production of specialty chemicals like ketene and diketene derivative products.
Valiant Laboratories Limited IPO Details:
| IPO Open Date | Not Available |
| IPO Close Date | Not Available |
| Listing Date | Not Available |
| Face Value | ₹10 per share |
| Price | Not Available |
| Lot Size | Not Available |
| Issue Size | 11,556,000 shares
(aggregating up to ₹[●] Cr) |
| Fresh Issue | 11,556,000 shares
(aggregating up to ₹[●] Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | Not more than 50% of the Offer |
| NII (HNI) Shares Offered | Not less than 15% of the Offer |
| Retail Shares Offered | Not less than 35% of the Offer |
| Promoters | Shantilal Shivji Vora And Dhanvallabh Ventures LLP |
Valiant Laboratories IPO
Wants To Apply Online 
Valiant Laboratories Limited IPO Financial Analysis:
| Particulars | FY-23
(in cr.) |
FY-22(in cr.)** | FY-21
(in cr.)** |
CAGR | ||
| 16 Aug-21 to Mar-21 | 1 April-21 to 15 Aug-21 | 31 Mar-22** | ||||
| Revenue from Operations | 333.91 | 209.14 | 82.38 | 291.52 | 182.37 | 35.3% |
| Other Income | 4.86 | 0.80 | 1.15 | 1.95 | 1.41 | |
| Cost of Goods Sold | 277.32 | 167.93 | 66.89 | 234.82 | 120.76 | 51.5% |
| Employee Cost | 4.61 | 2.23 | 0.84 | 3.06 | 2.71 | |
| Other expenses | 16.89 | 7.93 | 3.39 | 11.32 | 8.90 | |
| EBITDA | 39.95 | 31.85 | 12.42 | 44.27 | 51.41 | -11.8% |
| EBITDA margin% | 11.97% | 15.23% | 15.07% | 15.19% | 28.19% | |
| Depreciation | 1.56 | 1.62 | 0.87 | 2.49 | 2.61 | |
| Interest | 0.25 | 0.02 | 0.05 | 0.07 | 1.78 | |
| Profit / (loss) before tax | 38.14 | 30.21 | 11.50 | 41.71 | 47.02 | -9.9% |
| Total tax | 9.14 | 7.47 | 6.74 | 14.21 | 16.43 | |
| Profit / (loss) After tax | 29.00 | 22.74 | 4.75 | 27.50 | 30.59 | -2.6% |
| Profit / (loss) After tax margin% | 8.68% | 10.87% | 5.77% | 9.43% | 16.78% | |
Trade AnyTime AnyWhere With Elite Empower Mobile App
Check Valiant Laboratories IPO Allotment Status
Go Valiant Laboratories IPOallotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.
One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-
- To Valiant Laboratories IPO Allotment Status
- Go to Application Status
- Select Valiant Laboratories IPO
- Enter your PAN Number or Application Id or DP Client Id.
Valiant Laboratories IPO
Application Form
** Restated financials include period of Partnership Firm from 01/04/2020 to 15/08/2021
Valiant Laboratories Limited IPO Revenue from Operations:
| Segment | FY-23 (in cr.) | % | FY-22(in cr.)** | FY-21 (in cr.)** | % | CAGR | |||||
| 16 Aug-21 to Mar-21 | % | 1 April-21 to 15 Aug-21 | % | Mar-22 | % | ||||||
| Revenue from Operations | |||||||||||
| Sale of Manufactured Products | 331.75 | 99.35% | 207.89 | 99.40% | 81.40 | 98.81% | 289.29 | 99.23% | 180.55 | 99.00% | 35.6% |
| Sale of Traded Products | 0.36 | 0.11% | 0.35 | 0.17% | 0.08 | 0.10% | 0.43 | 0.15% | 0.02 | 0.01% | 348.5% |
| Other revenue from operation | 1.80 | 0.54% | 0.90 | 0.43% | 0.90 | 1.09% | 1.80 | 0.62% | 1.80 | 0.99% | 0.0% |
| Total | 333.91 | 100% | 209.14 | 100.00% | 82.38 | 100.00% | 291.52 | 100% | 182.37 | 100% | 35.3% |
** Restated financials include period of Partnership Firm from 01/04/2020 to 15/08/2021
Valiant Laboratories Limited IPO Major Shareholders:
| S.NO. | Name of the Shareholder | No. of Shares | % of pre-Offer shareholding |
| 1 | Dhanvallabh Ventures LLP | 20,350,000 | 62.50% |
| 2 | Shantilal Shivji Vora | 3,259,190 | 10.01% |
| 3 | Santosh Shantilal Vora | 3,259,190 | 10.01% |
| 4 | Kanchan Shantilal Vora | 1,614,690 | 4.96% |
| 5 | Paresh Shashikant Shah | 4,067,690 | 12.49% |
| Total | 32,550,760 | 99.97% |
Valiant Laboratories Limited IPO Strengths:
-
Valiant Laboratories Limited has grown rapidly over the last few years primarily due to the vision and dynamism demonstrated by the company’s promoter Shantilal Shivji Vora and he continues to be the driving force for the company. Additionally, its board of directors comprise of a combination of industry specialists and management executives who bring significant value and experience to the company. Its management team also consists of professionals with several years of experience and knowledge in the industry.
-
With a focus on a solid balance sheet and enhanced profitability, the company works to maintain a healthy financial position. For the Fiscal 2023, Fiscal 2022 and Fiscal 2021, its revenue from operations were ₹333.91 crores, ₹291.52 crores and ₹182.37 crores, respectively. Its revenue from operations grew at a CAGR of 23.90% between Fiscal 2017 and Fiscal 2023.
-
Valiant Laboratories Limited has shown a decreasing trend of import of said raw material and purchasing the same through its ultimate holding company i.e. Valiant Organics Limited which leads to better coordination, competitive pricing, eliminating hefty transportation and reduced delivery transit time.
-
Valiant Laboratories Limited’s Manufacturing Facility is strategically located at a distance of about 150 kms from JNPT Port, Maharashtra and approximately 110 kms from the company’s registered office at Mulund West, Maharashtra, which ensures that it has ready access to port facilities, thereby providing it with a cost and logistical advantage.
Valiant Laboratories Limited IPO Risk Factors:
-
Valiant Laboratories Limited is dependent on a few customers for a major part of its revenues. Its sales are concentrated to a few customers with its top 10 customers contributing up to 42.61%, 36.87% and 48.01%, of its revenues during the Fiscal 2023, Fiscal 2022 and Fiscal 2021, respectively. Furthermore, the company does not sign into long-term contracts with its clients, so any termination of the current ones could have an adverse impact on operations.
-
In relation to the capital expenses that will be incurred for the planned facility and are expected to be financed with the proceeds of the Issue, Valiant Laboratories Limited has not yet made any orders. In the event of any delay in placing the orders, may result in time and cost over-runs and its business, prospects and results of operations may be negatively affected.
-
Valiant Laboratories Limited is dependent on its R&D activities as it plays an important role for its business and its future results of operations depend on these activities to a significant degree. If the company does not successfully improve its existing products or continue its product portfolio expansion in a timely and cost-effective manner, the financial condition and cash flows may have a detrimental effect.
-
During the Fiscal 2023, Fiscal 2022 and Fiscal 2021 the company incurred a heavy capital expenditure of ₹7.36 crores, ₹6.46 crores and ₹1.67 crores, respectively. The company may require substantial financing for business operations and capital expenditure for future operations and the failure to obtain additional financing on terms commercially acceptable to it may adversely affect its future profitability.
Valiant Laboratories Limited IPO Prospectus:
- Valiant Laboratories Limited IPO DRHP- https://www.sebi.gov.in/filings/public-issues/jun-2023/valiant-laboratories-limited-drhp_72352.html
- Valiant Laboratories Limited IPO RHP-
Valiant Laboratories Limited IPO Registrar to the offer:
Link Intime India Private Limited
Tel: +91 8108114949
E-mail: valiantlaboratories.ipo@linkintime.co.in
Investor Grievance E-mail: valiantlaboratories.ipo@linkintime.co.in
Contact Person: Shanti Gopalkrishnan
Website: www.linkintime.co.in
SEBI Registration No: INR000004058